Danaher (NYSE:DHR) Given New $265.00 Price Target at Citigroup

Danaher (NYSE:DHR) had its price target reduced by equities research analysts at Citigroup from $285.00 to $265.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the conglomerate’s stock. Citigroup’s price target indicates a potential upside of 18.75% from the company’s current price.

A number of other equities research analysts also recently weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $277.00 price target (down from $299.00) on shares of Danaher in a research note on Thursday. JPMorgan Chase & Co. cut their price objective on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research report on Friday, December 13th. Raymond James dropped their price target on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Finally, Stephens reiterated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Stock Down 0.3 %

DHR traded down $0.57 on Thursday, reaching $223.16. 6,666,404 shares of the company traded hands, compared to its average volume of 3,626,230. The company has a market cap of $161.19 billion, a price-to-earnings ratio of 42.59, a PEG ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock’s 50 day moving average price is $235.89 and its 200-day moving average price is $253.45. Danaher has a 52-week low of $221.34 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter in the previous year, the company posted $2.09 EPS. On average, sell-side analysts expect that Danaher will post 7.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Danaher

Large investors have recently added to or reduced their stakes in the company. FMR LLC raised its position in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Van ECK Associates Corp grew its stake in shares of Danaher by 6,862.7% in the 4th quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after purchasing an additional 916,513 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares during the period. Finally, Montrusco Bolton Investments Inc. boosted its stake in Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.